Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹1 Cr
P/E Ratio
--
P/B Ratio
-0.5
Industry P/E
37.25
Debt to Equity
0
ROE
0 %
ROCE
0 %
Div. Yield
0 %
Book Value
--
EPS
-0.78
CFO
₹-2.45 Cr
EBITDA
₹-0.65 Cr
Net Profit
₹-0.70 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Raymed Labs
| 10.07 | -- | 10.07 | 52.40 | 26.12 | -- | -2.62 |
|
BSE Healthcare*
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
BSE Small Cap#
| -12.38 | 0.32 | -4.19 | 2.45 | 17.96 | 35.18 | 15.87 |
|
2024
|
2023
|
|
|---|---|---|
|
Raymed Labs
| 17.07 | 32.26 |
|
BSE Small Cap
| 29.04 | 47.52 |
|
BSE Healthcare
| 43.09 | 36.97 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 425.60 | 6,920.24 | 25.22 | 12.5 | |
| 5,063.50 | 8,422.94 | 35.6 | 43.77 | |
| 680.85 | 6,674.72 | 75.6 | 4.01 | |
| 653.45 | 6,028.82 | 22.37 | 12.68 |
No Review & Analysis are available.
Raymed Labs Limited manufactures allopathic medicines in India. The company was incorporated in 1992 and is based in Noida, India.
Incorporated
1992
Chairman
--
Managing Director
--
Headquarters
Gautam Budh Nagar, Uttar Pradesh
Website
Looking for more details about Raymed Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Raymed Labs Ltd stood at ₹ 1 Cr as on 31-Dec-24
The share price of Raymed Labs Ltd is ₹3.17 (BSE) as of 24-Mar-2025 IST. Raymed Labs Ltd has given a return of 26.12% in the last 3 years.
Raymed Labs Ltd has a market capitalisation of ₹ 1 Cr as on 24-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Raymed Labs Ltd is -0.50 times as on 24-Mar-2025, a 110% discount to its peers’ median range of 5.15 times.
Since, TTM earnings of Raymed Labs Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Raymed Labs Ltd and enter the required number of quantities and click on buy to purchase the shares of Raymed Labs Ltd.
Raymed Labs Limited manufactures allopathic medicines in India. The company was incorporated in 1992 and is based in Noida, India.
The prominent promoters of Raymed Labs Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Nishant N Bajaj |
9.05%
|
|
Prashant Nathmal Bajaj |
7.09%
|
|
Hitesh Bajoria |
6.68%
|
|
Urmila Hansraj Sharma |
4.73%
|
The chairman of the company is , and the managing director is .
There is no promoter pledging in Raymed Labs Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
6,029
|
| Raymed Labs Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-3722.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Raymed Labs Ltd was ₹0 Cr.
₹0.15
(
